Summary Terremoto Biosciences has raised $108 million in a Series C financing to advance its covalent targeted protein degradation platform, including AKT1-targeting degraders into clinical development. What Happened The company secured $108M to support progression of its degrader pipeline, with…
Summary Neomorph has raised $100 million to advance its molecular glue platform, reinforcing investor confidence in next-generation targeted protein degradation technologies. What Happened The company secured $100M in financing to expand development of its molecular glue therapeutics platform. The announcement…
Summary Allogene Therapeutics announced it will present an interim futility analysis from its pivotal Phase 2 ALPHA3 trial of an allogeneic CAR-T therapy in first-line consolidation for large B-cell lymphoma (LBCL), with data expected on April 13, 2026. What Happened…
Summary Cartherics and Catalent have expanded their manufacturing partnership to support development and commercialization of iPSC-derived CAR-NK cell therapies. The agreement strengthens access to Catalent’s cGMP-compliant iPSC platform, supporting multiple programs including lead candidate CTH-401. What Happened Cartherics entered an…
Summary Life Biosciences has raised $80 million to support clinical development of its anti-aging gene therapy program, marking a notable financing event in the longevity and gene therapy space. What Happened The company secured $80M in financing to advance its…
Summary Pfizer announced the closure of its South San Francisco research site, citing underutilization and broader pressures in the biotech funding environment. The move reflects ongoing post-pandemic restructuring across large pharmaceutical companies and signals shifts in R&D footprint strategy. What…
Summary Gilead Sciences has agreed to acquire German biotech Tubulis in a deal worth up to $5 billion, significantly expanding its antibody-drug conjugate (ADC) platform capabilities. The transaction underscores the strategic importance of ADC technologies in next-generation oncology pipelines. What…
Summary The FDA has extended the review timeline for Orca Bio’s biologics license application (BLA) for Orca-T, a high-precision allogeneic cell therapy for hematologic malignancies. The updated PDUFA date has been moved from April 6, 2026 to July 6, 2026…
Summary Astellas has declined to exercise its option on AviadoBio’s AAV-based gene therapy program targeting frontotemporal dementia (FTD), but the program will continue through nonprofit funding support. The development highlights an alternative pathway for sustaining high-risk, rare-disease programs despite pharmaceutical…
Summary The RNA therapeutics field is approaching a key inflection point with the anticipated initiation of the first clinical trial of engineered transfer RNA (tRNA) therapy, led by emerging players such as Alltrna. This modality targets nonsense mutations, representing a…
